Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ACC 2025: EVOLUT Low Risk 5Y Outcomes
Author(s): Michael J Reardon Added: 7 months ago
ACC 2025 - EVOLUT Low-Risk findings show the Medtronic TAVR system is a safe and effective treatment for aortic stenosis vs surgical valves at five years.Dr Michael Reardon (Houston Methodist, Texas, US) joins us onsite at ACC to discuss the EVOLUT Low Risk trial (NCT02701283; Medtronic Cardiovascular), investigating the safety and effectiveness of the Medtronic TAVR system compared to surgical… View more

Intervention
Lifetime Management of Aortic Stenosis with Dr Samineh Sehatbakhsh
Author(s): Samineh Sehatbakhsh Added: 2 months ago
Explore comprehensive lifetime management strategies for aortic stenosis with Dr Samineh Sehatbakhsh, addressing the evolving landscape of treatment options for patients across all risk categories.This detailed presentation, part of the Complex Cases track, examines the critical decision-making process between TAVR and surgical aortic valve replacement in the modern era. Dr Sehatbakhsh addresses… View more

Intervention
Complex Cases: Aortic Stenosis in Women with Prof Karam
Author(s): Nicole Karam Added: 3 months ago
Discover the sex-specific challenges in aortic stenosis diagnosis and management with Prof Nicole Karam (European Hospital Georges Pompidou, Paris, FR).This presentation, part of a comprehensive two-part series on complex cases in interventional cardiology, explores the critical pathophysiological differences between men and women that impact diagnostic approaches and therapeutic decision-making… View more

Demographic

Intervention
TCT 23: Four-Year Outcomes from the EVOLUT Low Risk Trial
Author(s): Michael J Reardon Added: 2 years ago
TCT 23 - In this succinct interview, we are joined by Dr Michael Reardon (Houston Methodist, US) to discuss the four-year outcomes from the EVOLUT Low-Risk Trial (NCT03635424), sponsored by Medtronic. The EVOLUT Low-risk trial is a multicenter, prospective, single-arm study which aimed to assess the procedural safety and efficacy of the Medtronic TAVR system in 150 patients with bicuspid… View more

Intervention
TCT 23: 5Y Outcomes From the PARTNER 3 Low-Risk Trial
Author(s): Martin B Leon Added: 1 year ago
TCT 23 - In this short virtual interview, we are joined by Dr Martin B Leon (Columbia University Medical Center, US) to discuss the 5-year outcomes from Edwards' PARTNER 3 low-risk trial (NCT02675114).PARTNER 3 is a randomized, prospective, multicenter trial that aimed to determine the safety and effectiveness of the SAPIEN 3 transcatheter heart valve in patients with severe calcific aortic… View more

Intervention
Aortic Stenosis and TAVI: New Trials, Devices and Data
Author(s): Roxana Mehran , Martin Swaans , Haim Danenberg , et al Added: 2 years ago
In this video series, first presented at the ESC Congress 2023 held in Amsterdam, Prof Roxana Mehran, Dr Antoinette Neylon, Dr Martin Swaans, Prof Raphael Rosenhek and Prof Haim Danenberg discuss the Expand II TAVR pivotal trial design and the rational for investigating the treatment of moderate aortic stenosis patients with Evolut™ TAVI, provide practical Echo imaging recommendations to improve… View more

Heart Failure

Intervention
EuroPCR 24: The NOTION-2 Study
Author(s): Ole De Backer Added: 1 year ago
EuroPCR 24 - We are joined onsite by Prof Ole De Backer (Rigshospitalet, DK) to discuss the findings from the NOTION-2 Study. (NCT02825134).NOTION-2 is a randomized, multicenter trial which aimed to investigate transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in 376 patients under 75 years of age with severe aortic valve stenosis in regard to intra-… View more

Intervention
Managing Hypertension in CVD: How Low Can We Go?
Author(s): Yassir Javaid , Michel Burnier , Mariya Tokmakova , et al Start date: Jun 25, 2025
Join an expert panel of internationally recognised cardiovascular specialists for a CME-accredited* webinar on the latest strategies in hypertension management for patients with cardiovascular disease. Chaired by Dr Yassir Javaid (Imperial College Healthcare NHS Trust, London, UK), with Prof Michel Burnier (University Hospital of Lausanne, Lausanne, CH) Prof Mariya Tokmakova (Medical University… View more

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
Prasad Gunasekaran
Research Area(s) / Expertise:

Coronary Interventions

Structural Intervention

 Job title: Interventional Cardiologist
Dr Prasad Gunasekaran is an interventional cardiologist with a focus on transcatheter structural heart interventions from Mercy Heart Hospital, Springfield, MO. He holds a special interest in intracoronary imaging with IVUS/OCT and vulnerable coronary plaques. His clinical practice involves use of intracardiac echo (ICE) for structural heart interventions and low-contrast precision percutaneous… View more
ACC.24: The DEDICATE-DZHK6 Trial
Author(s): Moritz Seiffert Added: 1 year ago
ACC.24 — Investigator Dr Moritz Seiffert (University Heart and Vascular Center Hamburg, DE) joins us onsite at ACC to discuss the findings of the DEDICATE-DZHK6 Trial (NCT03112980).This randomized controlled, multi-center trial aimed to investigate whether transcatheter aortic valve implantation (TAVI) is non-inferior to surgical aortic valve replacement (SAVR) in patients with symptomatic severe… View more

Intervention